| Articolul precedent |
| Articolul urmator |
 |
 230 0 |
 SM ISO690:2012AUTOR, Nou, AUTOR, Nou, MAZUR, Lilia. Change of c-reactive protein and tumor necrosis factor-α levels in Diabetes mellitus type 2 and l-arginine-l-glutamate. In: MedEspera, Ed. 1, 17 mai 2012, Chişinău. Chişinău: "Tipografia-Sirius" SRL, 2012, p. 11. ISBN 978-9975-57-030-5. |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
| MedEspera 2012 | ||||||
|
Conferința "MedEspera" 1, Chişinău, Moldova, 17 mai 2012 | ||||||
|
||||||
| Pag. 11-11 | ||||||
|
||||||
 Descarcă PDF |
||||||
| Rezumat | ||||||
The Purpose of our study was to determine C-reactive protein (CRP) and tumor necrosis factor- α (TNF-α) levels in patients with nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus and their correction with NO synthesis precursor L-arginine-L-glutamate. Materials and methods: We examined 30 patients with type 2 diabetes aged 35 to 65, who had symptoms of NAFLD. The functional state of liver, changes in plasma levels of pro-inflammatory cytokine TNF-α and CRP were evaluated in patients treated with L-arginine-L-glutamate. Results: It was determined that in patients with type 2 diabetes and NAFLD the levels of TNF-α and CRP were significantly higher than in patients with type 2 diabetes and healthy subjects. A statistically significant decrease of TNF-α and CRP levels was established 8-10 days after the beginning of administration of L-arginine-L-glutamate in patients with type 2 diabetes and NAFLD as compared to the control group (patients with type 2 diabetes who did not take L-arginine-L-glutamate). The treatment was followed by improvement of functional liver tests (bilirubin, general cholesterol, triglycerides, β-lipoproteins, alaninaminotransferase, and general protein) and liver ultrasound picture. Conclusions: Thus, administration of the NO-synthesis precursor L-arginine-L-glutamate in patients with diabetes mellitus type 2 and NAFLD contributes to the decrease of systemic inflammation, in particular - C-reactive protein and tumor necrosis factor- α and improvement of functional liver tests. |
||||||
| Cuvinte-cheie C-reactive protein, tumor necrosis factor- α, diabetes mellitus, L-arginine-L-glutamate |
||||||
|
DataCite XML Export
<?xml version='1.0' encoding='utf-8'?> <resource xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns='http://datacite.org/schema/kernel-3' xsi:schemaLocation='http://datacite.org/schema/kernel-3 http://schema.datacite.org/meta/kernel-3/metadata.xsd'> <creators> <creator> <creatorName>Autor, N.</creatorName> </creator> <creator> <creatorName>Autor, N.</creatorName> </creator> <creator> <creatorName>Mazur, L.</creatorName> </creator> </creators> <titles> <title xml:lang='en'>Change of c-reactive protein and tumor necrosis factor-α levels in Diabetes mellitus type 2 and l-arginine-l-glutamate</title> </titles> <publisher>Instrumentul Bibliometric National</publisher> <publicationYear>2012</publicationYear> <relatedIdentifier relatedIdentifierType='ISBN' relationType='IsPartOf'>978-9975-57-030-5</relatedIdentifier> <subjects> <subject>C-reactive protein</subject> <subject>tumor necrosis factor- α</subject> <subject>diabetes mellitus</subject> <subject>L-arginine-L-glutamate</subject> </subjects> <dates> <date dateType='Issued'>2012</date> </dates> <resourceType resourceTypeGeneral='Text'>Conference Paper</resourceType> <descriptions> <description xml:lang='en' descriptionType='Abstract'><p>The Purpose of our study was to determine C-reactive protein (CRP) and tumor necrosis factor- α (TNF-α) levels in patients with nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus and their correction with NO synthesis precursor L-arginine-L-glutamate. Materials and methods: We examined 30 patients with type 2 diabetes aged 35 to 65, who had symptoms of NAFLD. The functional state of liver, changes in plasma levels of pro-inflammatory cytokine TNF-α and CRP were evaluated in patients treated with L-arginine-L-glutamate. Results: It was determined that in patients with type 2 diabetes and NAFLD the levels of TNF-α and CRP were significantly higher than in patients with type 2 diabetes and healthy subjects. A statistically significant decrease of TNF-α and CRP levels was established 8-10 days after the beginning of administration of L-arginine-L-glutamate in patients with type 2 diabetes and NAFLD as compared to the control group (patients with type 2 diabetes who did not take L-arginine-L-glutamate). The treatment was followed by improvement of functional liver tests (bilirubin, general cholesterol, triglycerides, β-lipoproteins, alaninaminotransferase, and general protein) and liver ultrasound picture. Conclusions: Thus, administration of the NO-synthesis precursor L-arginine-L-glutamate in patients with diabetes mellitus type 2 and NAFLD contributes to the decrease of systemic inflammation, in particular - C-reactive protein and tumor necrosis factor- α and improvement of functional liver tests.</p></description> </descriptions> <formats> <format>application/pdf</format> </formats> </resource>
|
|
|
